Cargando…

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue

In most clinical trials, thiazolidinediones do not show any relevant anti-cancer activity when used as mono-therapy. Clinical inefficacy contrasts ambiguous pre-clinical data either favoring anti-tumor activity or tumor promotion. However, if thiazolidinediones are combined with additional regulator...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heudobler, Daniel, Rechenmacher, Michael, Lüke, Florian, Vogelhuber, Martin, Pukrop, Tobias, Herr, Wolfgang, Ghibelli, Lina, Gerner, Christopher, Reichle, Albrecht
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274845/ https://www.ncbi.nlm.nih.gov/pubmed/30424016 http://dx.doi.org/10.3390/ijms19113540

Ejemplares similares

Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis
por: Heudobler, Daniel, et al.
Publicado: (2018)

Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue—Going Beyond Apoptosis Induction
por: Heudobler, Daniel, et al.
Publicado: (2019)

Drug Repurposing by Tumor Tissue Editing
por: Lüke, Florian, et al.
Publicado: (2022)

Editorial: Anakoinosis: An Innovative Anticancer Therapy Targeting the Aberrant Cancer Tissue Homeostasis
por: Heudobler, Daniel, et al.
Publicado: (2021)

Editorial: Anakoinosis for promoting tumor tissue editing: Novel therapeutic opportunities for establishing clinically relevant tumor control by targeting tumor plasticity
por: Heudobler, Daniel, et al.
Publicado: (2022)

Continuous Complete Remission in Two Patients with Acute Lymphoblastic Leukemia and Severe Fungal Infection Following Short-Term, Dose-Reduced Chemotherapy
por: Lüke, Florian, et al.
Publicado: (2021)

Editorial: Tumor Systems Biology: How to Therapeutically Redirect Dysregulated Homeostasis in Tumor Systems (i.e., Anakoinosis)
por: Reichle, Albrecht, et al.
Publicado: (2020)

Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial
por: Walter, I., et al.
Publicado: (2017)

All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma
por: Fante, Matthias A., et al.
Publicado: (2023)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin’s Disease
por: Lüke, Florian, et al.
Publicado: (2021)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)
por: Heudobler, Daniel, et al.
Publicado: (2021)

All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma
por: Fante, Matthias A., et al.
Publicado: (2022)

Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience
por: Schelker, Roland Christian, et al.
Publicado: (2018)

Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia
por: Hart, Christina, et al.
Publicado: (2015)

Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
por: Wang, Limei, et al.
Publicado: (2014)

Gemcitabine Maintenance Therapy in Patients With Metastasized Soft Tissue Sarcomas
por: Harrer, Dennis Christoph, et al.
Publicado: (2021)

Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists
por: Liberato, Marcelo Vizoná, et al.
Publicado: (2012)

A Computational Model of Tumor Growth and Anakoinosis
por: Pantziarka, Pan, et al.
Publicado: (2019)

Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS/AML
por: Heudobler, Daniel, et al.
Publicado: (2018)

Effects of peroxisome proliferator activated receptors (PPAR)-γ and -α agonists on cochlear protection from oxidative stress
por: Sekulic-Jablanovic, Marijana, et al.
Publicado: (2017)

Case Report: Extramedullary Acute Promyelocytic Leukemia: An Unusual Case and Mini-Review of the Literature
por: Harrer, Dennis Christoph, et al.
Publicado: (2022)

Underexpression of peroxisome proliferator-activated receptor (PPAR)γ in PAX8/PPARγ-negative thyroid tumours
por: Marques, A R, et al.
Publicado: (2004)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
por: Harrer, Dennis Christoph, et al.
Publicado: (2020)

Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy
por: Kattner, Anna-Sophia, et al.
Publicado: (2020)

Benzoxazinones as Human Peroxisome Proliferator Activated Receptor Gamma (PPARγ) Agonists: A Docking Study Using Glide
por: Das, N., et al.
Publicado: (2011)

Coronavirus disease 2019 induces multi‐lineage, morphologic changes in peripheral blood cells
por: Lüke, Florian, et al.
Publicado: (2020)

Biomodulatory Treatment With Azacitidine, All-trans Retinoic Acid and Pioglitazone Induces Differentiation of Primary AML Blasts Into Neutrophil Like Cells Capable of ROS Production and Phagocytosis
por: Klobuch, Sebastian, et al.
Publicado: (2018)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

Oleamide activates peroxisome proliferator-activated receptor gamma (PPARγ) in vitro
por: Alexander, Stephen PH, et al.
Publicado: (2012)

Functions of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Gynecologic Disorders
por: Ren, Ping, et al.
Publicado: (2015)

Lowering Etoposide Doses Shifts Cell Demise From Caspase-Dependent to Differentiation and Caspase-3-Independent Apoptosis via DNA Damage Response, Inducing AML Culture Extinction
por: Bruni, Emanuele, et al.
Publicado: (2018)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

Peroxisome Proliferator-Activated Receptor (PPAR) γ and PPARα Agonists Modulate Mitochondrial Fusion-Fission Dynamics: Relevance to Reactive Oxygen Species (ROS)-Related Neurodegenerative Disorders?
por: Zolezzi, Juan M., et al.
Publicado: (2013)

PPARα-mediated peroxisome induction compensates PPARγ-deficiency in bronchiolar club cells
por: Karnati, Srikanth, et al.
Publicado: (2018)

A Novel Splicing Variant of Peroxisome Proliferator-Activated Receptor-γ (Pparγ1sv) Cooperatively Regulates Adipocyte Differentiation with Pparγ2
por: Takenaka, Yasuhiro, et al.
Publicado: (2013)

PPARγ Agonists: Blood Pressure and Edema
por: Blazer-Yost, Bonnie L.
Publicado: (2010)

PPARγ Agonists: Emergent Therapy in Endometriosis
por: Vallée, Alexandre, et al.
Publicado: (2021)

Ultrasound Assisted a Peroxisome Proliferator-Activated Receptor (PPAR)γ Agonist-Loaded Nanoparticle-Microbubble Complex to Attenuate Renal Interstitial Fibrosis
por: Wei, Shuping, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_18uucue66b3jmlqc4jo4bkuh81